2Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegrin: a novel secreted protein involved in the regulation of bone density [J] . Cell, 1997, 89 (2) :309-319.
3Yasuda H, Shima N, Nakagawa N, et al. Identity of osteoclasts to genesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIFinhibits osteoclastogenesis in vitro [ J ] . Endocrinology, 1998, 139 (3) :1329-1337.
4Tan KB, Harrop J, Reddy M, et al. Characterization of an novel TNF like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and nonhematopietic cells [J] . Gene, 1997, 204:35-46.
5Tomoyasu A, Goto M, Fujise N, et al. Characterize at ionofmonomeric and homodimeric forms of osteoclastogenesis inhibitor factors [ J] . Bio ehem Biophys Res Com,1998, 245: 382-387.
6Tsuda E, Goto M, Mochizuki SI, et al. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis [ J ] . Bio Chemical and Biophysical Research Communications, 1997, 234: 137-142.
8Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin(OPG) ligand is a cytokine that regulates osteoclast differentiation and activation [ J ] . Cell, 1998, 93 : 165-176.
9Roodman GD. Biology of osteoclast activation in cancer[J] . Clin Oncol, 2001, 19 (17) :3562-3571.
10Anderson DM, Maraskovsky E, Billingsley WL, et al.Ahomologue of the TNF receptor and its ligand enhance T cell growth and dendritic cell function [ J ] . Nature,1977, 390 (6656) :175-179.
